Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
about
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasHearing improvement after bevacizumab in patients with neurofibromatosis type 2Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Recommendations for imaging tumor response in neurofibromatosis clinical trials.Identifying predictors of early growth response and adverse radiation effects of vestibular schwannomas to radiosurgeryErlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Optimizing biologically targeted clinical trials for neurofibromatosis.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Tumor pseudoprogression following radiosurgery for vestibular schwannomaA rare retroperitoneal schwannoma in a patient with neurofibromatosis Type 2.Contemporary management of acoustic neuromas.Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.Pretreatment ADC Values Predict Response to Radiosurgery in Vestibular Schwannomas.Therapeutics for childhood neurofibromatosis type 1 and type 2.Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.Vestibular schwannomas: Accuracy of tumor volume estimated by ice cream cone formula using thin-sliced MR images.Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.Neurofibromatosis Type 2.Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
P2860
Q30359059-550A5916-F30B-4E87-9796-34DC3DECF5B6Q30387415-3309B03D-B3F1-4AA0-BB8F-8A892956BBB5Q30422022-0BC5B694-B16F-49F6-8929-528DF8AE2DE6Q30425757-6B242E98-7C65-4183-B1BA-E245F21E0024Q30427640-4E995116-8DB2-44E1-B90D-CB5BC18965E8Q30438136-B7BA9014-1E3A-42EF-93D3-87BB25CFA0EBQ30438898-1C697C63-A3E1-4803-A100-A6B505A4C0BFQ30450038-DCA5A063-974F-4F7C-8588-5C121A1A4140Q30459606-2C1CFF69-B66C-4257-A3F0-566E86FDE6C3Q33816942-DC880246-B44F-4802-9849-8B5EB50810E0Q37873874-D50B4167-04B3-40AD-8AC4-6D8DBD465D94Q38430591-08A0FD73-9287-40A6-8A09-2FE8ADF2DBD0Q38837570-CEE51EBB-7C20-46B3-A6D0-85CA4358CE8CQ39716494-6AEBFE2D-B4CB-43AD-BAF5-37C5FBE6F2EFQ39794311-2BC6E31C-C6D8-4502-B7E3-0590771E0A95Q47424261-CFB5198F-918E-4B80-B164-206134910E20Q47663303-5F699D9F-F194-492D-BFE5-F58EA26766C7Q50041718-7CA96177-6BDD-452A-BEA3-5BC34FC7A78DQ50352494-A98D1C47-CA6B-4701-8178-E72896E52B78Q50352841-79D179E5-B7A5-4D01-A0F4-3BE5734AF2C2Q54191697-79CBE43C-2442-452A-8183-42A9FB59A494Q57266579-800BE1C1-E387-40F7-8E87-0ADBD2855A5E
P2860
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Suggested response criteria fo ...... related vestibular schwannoma.
@ast
Suggested response criteria fo ...... related vestibular schwannoma.
@en
type
label
Suggested response criteria fo ...... related vestibular schwannoma.
@ast
Suggested response criteria fo ...... related vestibular schwannoma.
@en
prefLabel
Suggested response criteria fo ...... related vestibular schwannoma.
@ast
Suggested response criteria fo ...... related vestibular schwannoma.
@en
P2093
P2860
P1476
Suggested response criteria fo ...... related vestibular schwannoma.
@en
P2093
A Gregory Sorensen
Chris Halpin
D Bradley Welling
Fred G Barker
Gordon J Harris
Jaishri O Blakeley
Jay S Loeffler
Michael J McKenna
Scott R Plotkin
Susan M Chang
P2860
P2888
P356
10.1007/S11060-009-9867-7
P577
2009-05-09T00:00:00Z
P6179
1024772214